Although TKIs targeting the VEGFR pathway are more prone to causing hypertension in RCC patients, pazopanib has the highest documented rate of treatment-induced hypertension in patients with thyroid carcinoma, with all-grade hypertension occurring in 54.1 % of cases [65], versus 38.2 % in RCC patients [66, 67]. This evidence concerns the gene KDR and Hypertension.